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Abstract
Located in the critical 1p36 microdeletion region, the chromodomain helicase DNA-binding protein 5 (CHD5) gene encodes 
a subunit of the nucleosome remodeling and deacetylation (NuRD) complex required for neuronal development. Pathogenic 
variants in six of nine chromodomain (CHD) genes cause autosomal dominant neurodevelopmental disorders, while CHD5-
related disorders are still unknown. Thanks to GeneMatcher and international collaborations, we assembled a cohort of 16 
unrelated individuals harboring heterozygous CHD5 variants, all identified by exome sequencing. Twelve patients had de 
novo CHD5 variants, including ten missense and two splice site variants. Three familial cases had nonsense or missense 
variants segregating with speech delay, learning disabilities, and/or craniosynostosis. One patient carried a frameshift variant 
of unknown inheritance due to unavailability of the father. The most common clinical features included language deficits 
(81%), behavioral symptoms (69%), intellectual disability (64%), epilepsy (62%), and motor delay (56%). Epilepsy types 
were variable, with West syndrome observed in three patients, generalized tonic–clonic seizures in two, and other subtypes 
observed in one individual each. Our findings suggest that, in line with other CHD-related disorders, heterozygous CHD5 
variants are associated with a variable neurodevelopmental syndrome that includes intellectual disability with speech delay, 
epilepsy, and behavioral problems as main features.
Introduction
The chromodomain-helicase-DNA-binding protein 5 gene 
(CHD5) belongs to a highly conserved family of genes 
encoding ATP-dependent chromatin remodeling complex 
subunits comprising nine members, named CHD1–CHD9 
(Delmas et al. 1993; Woodage et al. 1997). CHD proteins 
carry out multiple functions essential for cell survival and 
embryonic development, including chromatin remodeling, 
transcriptional regulation, and DNA repair (Tyagi et al. 
2016). They are composed of two N-terminal chromodo-
mains important for histone tail binding, a central and con-
served SNF2-like helicase motif that uses ATP-hydrolysis 
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for chromatin remodeling, and a less-defined C-terminal 
DNA-binding domain (Delmas et al. 1993; Woodage et al. 
1997). The CHD protein family is further divided into three 
subfamilies based on the presence or absence of additional 
domains (Tyagi et al. 2016). Subfamily I (CHD1 and CHD2) 
features a C-terminal DNA-binding domain that preferen-
tially binds to AT-rich DNA motifs (Tyagi et al. 2016). Sub-
family III (CHD6 to CHD9) is characterized by the presence 
of additional C-terminal functional domains (BRK motif or 
SANT domain) that define their binding properties (Tyagi 
et al. 2016). CHD3, CHD4, and CHD5 are part of subfamily 
II, and, unlike other CHD members, they possess two N-ter-
minal Plant-Homeo Domains (PHD) with histone-binding 
activity. These three proteins represent mutually exclusive 
subunits of a large protein complex known as Nucleosome 
Remodeling and Deacetylase (NuRD) complex (Tyagi et al. 
2016).
Subfamily II members are characterized by different 
expression profiles, with CHD3 and CHD4 being ubiqui-
tously expressed, whereas CHD5 is mainly expressed in 
brain and testis (Marfella and Imbalzano 2007; Zhuang 
et al. 2014). Furthermore, the three encoded proteins have 
distinct, non-redundant properties and functions within the 
NuRD complex and neuronal defects induced by the specific 
knockdown of one subunit cannot be rescued by overex-
pression of another CHD protein (Nitarska et al. 2016). A 
coordinated sequential switch of these subunits is crucial for 
mouse cortical development (Nitarska et al. 2016). CHD3 
ensures proper layer specification,  CHD4 induces early pro-
liferation of the basal progenitors, while CHD5 mediates 
neuronal differentiation, radial migration, and neuronal cell 
identity (Nitarska et al. 2016). CHD5 is required both for 
activation of genes promoting neuronal differentiation pro-
grams and for repression of non-neuronal Polycomb target 
genes (Egan et al. 2013). Moreover, CHD5 directly interacts 
with the repressive H3K27me3 histone mark via its PHD 
and chromodomains (Egan et al. 2013).
All CHD genes are evolutionary constrained in human 
populations, with significantly fewer truncating and mis-
sense variants than expected by chance (Karczewski et al. 
2020), but only six of the nine CHD members have been 
associated with human disorders so far (Zentner et al. 2010; 
Merner et al. 2016; Weiss et al. 2016, 2020; Pilarowski et al. 
2018; Blok et al. 2018; Chen et al. 2020). Together with 
CHD6 and CHD9, CHD5 has not yet been associated with a 
human disease. However, CHD5 is located on chromosome 
1p36.31, a region commonly deleted in monosomy 1p36, 
and CHD5 haploinsufficiency was hypothesized to contrib-
ute to the clinical features of this syndrome, which include 
neurodevelopmental deficits (intellectual disability with 
limited language ability), delayed growth, hypotonia, sei-
zures, craniofacial and skeletal features, hearing and vision 
impairment, as well as cardiac anomalies (Shimada et al. 
2015). In this study, we assembled a cohort of 16 unrelated 
patients with de novo or inherited heterozygous variants in 
CHD5. Comparison of the clinical features of these affected 
subjects showed that genetic alterations of CHD5 are associ-
ated with a variable neurodevelopmental disorder frequently 
characterized by intellectual disability (ID), speech delay, 
motor delay, behavioral problems, and epilepsy.
Materials and methods
Following the identification by exome sequencing of a 
de novo missense variant in CHD5 in a patient with ID, 
autism spectrum disorder (ASD), and epilepsy, we col-
lected data from additional patients with CHD5 variants 
through GeneMatcher (Sobreira et al. 2015). We system-
atically included all patients with de novo variants as well 
as patients with either truncating or predicted damaging 
missense variants inherited from affected parents. Only 
patients without a detailed clinical history and/or inherit-
ance information were excluded from the study. Exome 
sequencing was performed at the respective institutions. 
Referring physicians provided detailed developmen-
tal, neurological, and behavioral history of the patients. 
Patient information was anonymized before data sharing. 
Variants were described on the CHD5 NM_015557.3 Ref-
Seq transcript using HGVS recommendations (den Dunnen 
et al. 2016) and classified according to ACMG guidelines 
(Richards et al. 2015). All variants have been submitted to 
the ClinVar Database and have been assigned the follow-
ing accession numbers: SCV001477999–SCV001478015. 
Multiple algorithms were used to assess the pathogenicity 
of CHD5 variants, including Mutation Taster, Polyphen-2, 
and SIFT (Ng 2003; Adzhubei et  al. 2010; Schwarz 
et al. 2014). Combined annotation-dependent depletion 
(CADD) scores (Rentzsch et al. 2019) were calculated 
for each variant using the GRCh37-v1.6 version (Online 
Resource Table 1). Prediction of the consequences of 
the two splicing variants were carried out with  Alamut® 
Visual, a mutation analysis software which includes a 
splicing module integrating a number of prediction algo-
rithms and splicing prediction data. Nucleotide conser-
vation across 100 vertebrate species was calculated for 
each variant using the PhastCons score obtained with the 
phastCons100way.UCSC.hg19 R package (Siepel 2005) 
and represents the probability that a given nucleotide is 
conserved (range 0–1). Codon conservation scores were 
calculated as the mean nucleotide conservation of each tri-
plet. Known CHD5 NM_015557.3 variants were retrieved 
from gnomAD v2.1.1 (Karczewski et al. 2020), restrict-






We report 16 different genetic alterations in CHD5, includ-
ing eleven missense variants [c.577C > T, p.(Arg193Trp); 
c.578G > A, p.(Arg193Gln), c.1279G > A, p.(Glu427Lys); 
c.2735C > T, p.(Ser912Phe); c.3250G > A, p.(Asp1084Asn); 
c . 3 3 7 1 C  >  T,  p . ( P ro 1 1 2 4 L e u ) ;  c . 3 4 0 7 G  >  A , 
p.(Arg1136His); c.3419A > T, p.(Asn1140Ile); c.4257C > G, 
p.(Ile1419Met); c.4463A > T, p.(Asp1488Val) and 
c.5141A > G, p.(Glu1714Gly)], one duplication of a single 
base leading to a frameshift [c.612dup, p.(Ser205Leufs*88)], 
two nonsense substitutions [c.940G > T, p.(Glu314*) and 
c.1786C > T, p.(Arg596*)], and two splice site variants 
(c.4079-3C > G and c.4171 + 1G > C). All variants were 
either absent from gnomAD or present with an allele fre-
quency below 0.0001% (Online Resource Table 1). All 
missense variants affect highly conserved amino acids of 
CHD5 (up to zebrafish, Online Resource Fig. 1), had CADD 
scores above 22, and were predicted to be damaging by at 
least two algorithms among Polyphen-2, SIFT, and Mutation 
Taster (Online Resource Table 1). The conservation score of 
nucleotides and corresponding codons calculated based on 
the alignment of 100 species additionally indicated that all 
the affected nucleotides, with the exception of c.4257C > G 
[resulting in p.(Ile1419Met)], were subject to a great level 
of conservation during evolution (score 1 in a 0 to 1 scale) 
(Online Resource Table 1).
Ten of the eleven missense substitutions and the two 
splice site variants occurred de novo in patients without 
family history, while one missense and the two nonsense 
variants segregated with neurodevelopmental phenotypes in 
three families (Fig. 1). The frameshift variant identified in 
Patient 3 was absent from her mother but inheritance could 
not be assessed further, since her father was not available 
for genetic analysis. Notably, one of the missense variants 
segregating in a larger family [p.(Arg193Trp)] occurred at 
the same highly conserved residue as one of the de novo 
missense variants [p.(Arg193Gln)]. Two de novo missense 
variants [p.(Asn1140Ile) and p.(Ile1419Met)] were mosaic 
in patients 11 and 14. Both mosaic variants, identified by 
WES, were present in less than 25% of the total reads on 
blood DNA and were confirmed by Sanger sequencing.
In addition to these sixteen predicted damaging variants, 
a de novo variant [c.815C > T, p.(Ala272Val)] absent from 
gnomAD was identified in a male patient (VUS 1, Online 
Resource Tables 1 and 2). This variant alters a poorly con-
served amino acid located outside of any known domain 
and is not predicted to alter splicing, but affects a highly 
Fig. 1  Family trees of the inherited mutations. In family 1, Individ-
ual III-3 corresponds to Patient 1. In family 2, Individual III-1 cor-
responds to Patient 4. In family 3, Individual III-1 corresponds to 
Patient 6. The variants in CHD5 identified in these three families are 
associated with incomplete penetrance and variable expressivity
 Human Genetics
1 3
conserved nucleotide (score 1) (Online Resource Fig. 1). 
Because of consistent benign predictions by all algorithms 
and a CADD score below 20, this variant was considered 
as of unknown significance despite its de novo occurrence.
Missense variants in CHD5 tend to cluster 
in functional domains
CHD5 comprises nine protein domains: an N-terminal domain 
of chromo domain-associated helicases (CHDNT), two PHD 
domains (PHD1 and PHD2) and two chromodomains (Chd1 
and Chd2) important for histone binding, one bipartite Helicase 
domain with ATPase catalytic activity, two conserved Domains 
with Unknown Function (DUF1087 and DUF1086), and a 
C-terminal domain B of chromo domain-associated CHD-like 
helicases (CHDCT2) mediating the interaction with GATA2D 
(Pierson et al. 2019) (Fig. 2a). The helicase, PHD, and C-ter-
minal regions are the most conserved and constrained domains 
(Samocha et al. 2017; Havrilla et al. 2019). Strikingly, missense 
variants with CADD scores above or equal to 22 reported in 
Fig. 2  Distribution of the CHD5 variants based on position and 
conservation of the affected amino acids. a Schematic represen-
tation of the CHD5 protein and its domains, with position of the 
identified mutations relative to exon and domain distribution. The 
CHDNT domain is indicated in yellow, the PHD domains in red, the 
Chd domains in green, the helicase domains in light blue, the DUFs 
domains in purple, and the CHDCT2 domain in lilac. Inherited vari-
ants are indicated in blue and de novo variants in black. Putative loss-
of-function variants are indicated with a triangle, likely pathogenic 
missense substitutions with a filled circle and the VUS with an empty 
circle. b Comparison of the distribution of the variants identified in 
our cohort with the synonymous and missense variants reported in 
gnomAD, with relative position of each affected CHD5 residue across 
the protein domains. c Comparison of a portion of the highly con-
served C-terminal Helicase domain among yeast SNF2 (black) and 
human CHD3 (red), CHD4 (green), and CHD5 (blue). Pathogenic 
missense substitutions altering residues in this domain are indicated 
with the color corresponding to the CHD protein where the vari-
ant was identified. The amino acids altered by the substitutions are 
indicated with a square whose color corresponds to the CHD protein 
where the variant was identified
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gnomAD alter fewer residues in the helicase C-terminal domain 
(17%) than in other regions (31–42%), contrary to gnomAD 
synonymous and missense variants with CADD scores below 
22, which appeared in 30% of the residues of this part of the 
helicase domain (other regions 25–60%) (Fig. 2b).
The 11 predicted damaging missense substitutions alter 
10 different amino acids and all but two affect a functional 
domain of CHD5: one variant affects the PHD2 domain, 
two variants each affect the CHDNT and the DUF1086 
domains, and four variants alter the C-terminal part of the 
helicase domain depleted in missense variants in gnomAD 
(Fig. 2a, b, Online Resource Fig. 1). Two missense sub-
stitutions in the helicase domain match positions altered 
by two previously published pathogenic variants in CHD3 
(Fig. 2c): CHD5-Asp1084 (Patient 8) corresponds to CHD3-
Asp1120, whereas CHD5-Arg1136 (Patient 10) corresponds 
to CHD3-Arg1172 (Blok et al. 2018). Additionally, Pro1124 
(Patient 9) is positioned within a stretch of amino acids that 
were found to be altered by missense substitutions of CHD3 
(Trp1158, Asn1159, and His1161) or CHD4 (Asp1147, 
Trp1148) (Blok et al. 2018; Weiss et al. 2020). Importantly, 
CHD3 residues Arg1172, Trp1158, and Asn1159 were 
proven essential for either the ATPase activity of or the abil-
ity to carry out chromatin remodeling (Blok et al. 2018).
The nonsense and frameshift variants identified in the 
present cohort are located in exons 5, 7, and 11, and are 
therefore predicted to result in transcripts that are subject to 
nonsense-mediated mRNA decay or to generate a truncated 
protein, if expressed. The two splice site variants are pre-
dicted to, respectively, abolish the acceptor and donor splice 
sites of exon 27 with high probability (Online Resource 
Fig. 2a, b). Since variants altering canonical splice sites fre-
quently lead to skipping of the corresponding exon, these 
two variants possibly induce the same in-frame deletion of 
the 93 nucleotides of exon 27. Given the preferential expres-
sion of CHD5 in brain and testis, we postulated that the 
effects of these two variants on CHD5 splicing could not 
be assessed. Surprisingly, we were able to amplify CHD5 
transcript from RNA extracted from blood and fibroblasts. A 
blood sample of Patient 13 could be subsequently obtained, 
and the resulting analysis showed the in-frame exclusion of 
exon 27 in the mutant allele, predicted to cause a deletion of 
31 amino acids at the protein level [p.(Glu1360_Ser1391de-
linsGly)] (Online Resource Fig.  2c). CHD5 splicing in 
Patient 12 could not be determined due to the impossibility 
to obtain additional material.
CHD5 variants are associated with developmental 
delay, intellectual disability, behavioral 
disturbances, epilepsy, and craniosynostosis
With the exclusion of Patient VUS1, the present cohort com-
prises seven females and nine males aged from 3 to 24 years 
(median age 9  years 6  months). Detailed phenotypical 
information for each patient is provided in Online Resource 
Table 2. For most patients, pregnancy was unremarkable, 
birth parameters were normal, and the neonatal period was 
uneventful. Measurements at the last evaluation were also 
mainly on average, with only two and four patients present-
ing with more than two standard deviations above the mean 
of growth standards for weight and height, respectively. 
The most frequent clinical features observed in this cohort 
are summarized in Table 1, and comprise speech delay 
(n = 13/16), behavioral disturbances (n = 11/16), epilepsy 
(n = 10/16), subtle facial dysmorphism (n = 11/16), motor 
delay (n = 9/16), intellectual disability (n = 9/14), hypoto-
nia (n = 7/14), and craniosynostosis (n = 3/7). The level of 
intellectual disability could be assessed for six of the nine 
patients and was moderate in two patients and severe in four. 
Four patients presented with normal IQ, with a full-scale IQ 
ranged between 85 and 105, and one patient was reported to 
have an IQ above average. Developmental milestones were 
delayed in the majority of the patients, with language acqui-
sition being more affected than motor development. Sitting 
and walking independently were achieved at a median age 
of 13 and 28 months, respectively. The first words were pro-
nounced at a median age of 24 months. Three patients were 
still non-verbal at 3, 9, and 24 years of age. Four patients 
with an age range between 11 and 22 years could only speak 
a few words. Dysphasia, stuttering, and echolalia were also 
reported in single patients. Autism spectrum disorder and 
obsessive–compulsive tendencies were the most frequently 
observed behavioral problems in this cohort. Self-injurious 
behavior, poor eye contact, outbursts of anger, and aggres-
sive behavior were also noted. Seizures occurred in more 
than half of the patients (n = 10) with a median age of onset 
of 10 months. The earliest onset was at day one and the lat-
est at 16 years of age. Patients could be divided into three 
groups based on the severity of the seizures, although a sig-
nificant intra-group variability was also observed: (1) three 
patients experienced one to five seizures only and were not 
under antiepileptic therapy; (2) three others had a general-
ized epilepsy and were still receiving antiepileptic drugs at 
the time of description; (3) four patients had a diagnosis 
of developmental and epileptic encephalopathy, and their 
EEG showed a suppression-burst pattern or hypsarrhythmia. 
Seizure types included generalized tonic–clonic febrile and 
afebrile seizures, infantile spasms, generalized staring spells, 
and myoclonus. Most of the patients were seizure-free at the 
time of the study with or without specific therapy. Hypoto-
nia was the most frequent finding upon neurological exami-
nation (n = 7/14), while dysmetria and ataxia were each 
reported in single patients. Brain Magnetic Resonance Imag-
ing (MRI) were mainly normal (n = 8/12) or showed non-
specific abnormalities. Dysmorphic facial features (Fig. 3) 
were rather nonspecific and did not suggest 1p36 deletion 
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syndrome. They comprised ear anomalies (n = 4/16), includ-
ing low set and posteriorly rotated ears, mildly cupped or 
smaller ears, prominent nasal bridge and tip (n = 3/16), short 
philtrum (n = 3/16), thin upper lip (n = 3/16), upslanting pal-
pebral fissures (n = 3/16), synophrys (n = 2/16), epicanthic 
folds (n = 2/16), frontal bossing (n = 2/16), and micrognathia 
(n = 2/16). However, no distinctive facial gestalt emerges 
from the series. Eye anomalies/visual impairment were 
noted in some patients but appeared inconsistent within the 
cohort. Notably, three patients displayed craniosynostosis 
(Fig. 3). Specifically, Patient 1 displayed sagittal craniosyn-
ostosis, Patient 4 had metopic craniosynostosis, and Patient 
5 was diagnosed with trigonocephaly. Craniosynostosis of 
Patients 1 (and of her cousin Individual 1-III-2, see Fig. 1) 
and of Patient 4 was diagnosed via computed tomography 
scans by craniofacial surgeons and was surgically corrected 
by cranial vault remodeling. Patient 5 did not undergo sur-
gery. Malformations of other organs were rare and restricted 
to individual patients.
Inherited variants are associated with intra‑familial 
variability and incomplete penetrance
Intellectual disability was not diagnosed in any of Patients 
1 (family 1), 4 (family 2), and 6 (family 3), and the clini-
cal features were variable within families (Fig. 1). Patient 
1, corresponding to individual 1-III-3 (Family 1, Genera-
tion III, Individual 3), presented with speech delay, normal 
motor development, and craniosynostosis. Speech delay was 
observed also in her cousins 1-III-1 and 1-III-2. Individual 
1-III-2 also displayed craniosynostosis, while Individual 
1-III-1 was additionally characterized by motor delay and 
oppositional defiant disorder (detailed clinical data of these 
two individuals are available in Online Resource Table 2). 
The p.(Arg193Trp) variant was inherited from the respective 
mothers, who are sisters. Detailed clinical features were not 
available for these subjects, but delayed speech was reported 
for 1-II-2, while her sister 1-II-3 was described as asympto-
matic. Suspected craniosynostosis was reported in the mater-
nal grand-mother 1-I-2, who was deceased.
Patient 4 (Individual 2-III-1) had normal development 
and intellectual abilities, but presented with a sensory pro-
cessing disorder, obsessive–compulsive tendencies, and was 
diagnosed with Asperger-like syndrome. He had hypotonia, 
metopic craniosynostosis, and tonic–clonic seizures over 
a period of 2 years that spontaneously resolved. His sister 
(2-III-2) displayed dyslexia, dysorthographia, dyscalculia, 
mood disorder, anxiety, and depression. The p.(Glu314*) 
variant present in the two siblings was inherited from their 
father (2-II-1), who showed dyslexia and borderline intel-
lectual disability.
Patient 6 (3-III-1) presented with mild motor delay and 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































dysmorphism, and strabismus. This family comprises three 
additional affected members: the proband’s sister (3-III-2) 
and his paternal uncle (3-II-1) displayed learning difficulties, 
while his father (3-II-2) had severe psychiatric issues and 
died from suicide.
Altogether, these data point to the existence of an intra-
familial phenotypic variability associated with inherited 
variants. Moreover, unaffected carriers were also reported 
in each family, indicating an incomplete penetrance. The 
lack of a thorough clinical history of each individual could 
also account for the reported differences.
Discussion
In this study, we report 13 sporadic cases and 3 families 
with predicted damaging variants altering highly conserved 
amino acids of CHD5. Patients with these genetic alterations 
display a broad spectrum of developmental disturbances, 
recurrently including developmental delay, learning diffi-
culties or intellectual disability, behavioral problems, sei-
zures, hypotonia, and craniosynostosis. Variants identified in 
patients include both missense substitutions altering highly 
conserved amino acids mainly located in functional domains 
and variants predicted to lead to haploinsufficiency by non-
sense-mediated mRNA decay (i.e., frameshift and nonsense 
variants). The probability that CHD5 is intolerant to haplo-
insufficiency, calculated by a recent study including 753,994 
individuals, is 0.93 (Collins et al. 2021). CHD5 is also 
catalogued among haploinsufficient genes by the Genome 
Aggregation Database (gnomAD), with a probability to be 
LOF intolerant (pLI) of 1 and an LOF observed/expected 
upper bound fraction (LOEUF) of 0.16. Furthermore, its 
missense Z-score (referring to the number of observed 
and expected missense variants within the same database) 
indicates that this gene is highly missense-constrained 
(Z-score = 5.32). These metrics indicate that variants dis-
rupting the coding sequence of CHD5 are counter-selected 
in human populations, and also suggest that they likely are 
disease-causing (Karczewski et al. 2020). Nevertheless, 25 
out of the 141,456 individuals present in gnomAD harbor 
CHD5 variants predicted to be associated with a LOF of 
the corresponding allele. Incomplete penetrance and vari-
able expressivity, as observed in the familial cases herein 
reported, could at least partially account for this finding. 
Furthermore, several of these truncating variants display an 
allelic imbalance lower than the 0.5 expected for heterozy-
gous variants, suggesting that some of them could be present 
only at the somatic state in older individuals.
CHD5 is known to play an important role in the con-
text of chromatin remodeling, which it achieves by means 
of its intrinsic ATPase activity and of its presence within 
the NuRD complex. Additionally, CHD5 is involved in the 
regulation of the expression of a subgroup of Polycomb 
target genes through the maintenance of the repressive 
H3K27me3 histone methylation mark (Egan et al. 2013). 
Hence, variants that disrupt CHD5 activity may impact 
the epigenetic landscape of cells in a way that results in 
transcriptional disturbances and possibly generates one or 
several episignatures that are unique for CHD5-related dis-
orders. The pathogenic mechanism(s) by which the variants 
described in this study contribute to different neurodevelop-
mental disturbances remains to be defined. Truncating and 
missense variants could alter the activity of CHD5 and of 
the NuRD complex in different ways, i.e., by either loss- or 
gain-of-function, and affect distinct aspects of the epigenetic 
processes related to the NuRD complex. These mechanisms 
might include haploinsufficiency of CHD5 within the com-
plex, impaired assembly or composition of the NuRD com-
plex, impaired binding to nucleosomes, or impaired ability 
to carry out ATP-dependent nucleosome remodeling. The 
sample size of our cohort and in particular the number of 
LOF variants was unfortunately too small to establish sig-
nificant genotype–phenotype correlations based on type and 
position of the variants. However, from this small cohort, we 
anticipate that missense substitutions might be more prone 
to cause epileptic phenotypes. Indeed, approximately half of 
the patients with missense variants (6/11) had developmental 
and epileptic encephalopathy and/or an ongoing antiepileptic 
treatment. In particular, three out of four patients with vari-
ants within the helicase domain displayed severe epilepsy 
(all three patients with West syndrome), while only one 
patient with variants outside this domain had severe epilepsy 
(suppression-burst) and two had controlled seizures. Thus, 
it seems that missense variants, particularly those located in 
the helicase domain, predispose to early onset epilepsy with 
a higher likelihood than LOF or missense variants outside 
this domain. However, this observation needs to be con-
firmed on larger sample sizes.
CHD5 is located on chromosome 1p36.31. Patients with 
CHD5 variants share nonspecific clinical features with the 
1p36 deletion syndrome, a disorder characterized by moder-
ate-to-severe intellectual disability, language deficits, hypo-
tonia, seizures, and distinctive facial features. Depending 
on the extent of the chromosomal deletion, CHD5 haploin-
sufficiency could contribute to the clinical features of this 
disorder or worsen the severity of intellectual disability, as 
previously suggested (Shimada et al. 2015). Furthermore, 
the genes responsible for epilepsy, a frequent feature of the 
1p36 deletion syndrome, have not yet been fully character-
ized. GABRD and KCNAB2 are considered likely candi-
dates for the epileptic phenotype, because patients with a 
deletion of these genes are more frequently epileptic than 
those without (Heilstedt et al. 2002; Shimada et al. 2015). 
However, CHD5 might also be held accountable for differ-
ent reasons. With the exception of a single patient (Shimada 
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et  al. 2015), CHD5 was always reported to be deleted 
together with KCNAB2, as CHD5 is adjacent and proximal 
to KCNAB2. Additionally, point variants in KCNAB2 have 
never been described thus far in association with epilepsy. 
Finally, 16/21 patients with a 1p36 deletion encompassing 
CHD5 were reported to display epilepsy, while 19/29 with 
retained CHD5 copy do not have epilepsy (Shimada et al. 
2015). RERE haploinsufficiency might also play a role in the 
epilepsy of some patients with the 1p36 deletion (Fregeau 
et al. 2016), but this gene is located proximally to CHD5 
and deleted only in patients with very large deletions [8/50 
in (Shimada et al. 2015)]. Thus, RERE haploinsufficiency 
would not explain the epilepsy of most patients with 1p36 
deletion. A similar reasoning applies to SPEN, a newly iden-
tified ID-associated gene with rare seizures, which is proxi-
mal to RERE (Radio et al. 2021). Taken together, these data 
suggest that several genes may be involved in the epilepsy 
phenotype of the 1p36 deletion syndrome and that CHD5 
represents one of its potential modifiers. Notably, seizures 
are a frequent feature of patients with CHD5 point variants 
as well, hence supporting the epileptogenic role of CHD5 in 
the context of the 1p36 deletion syndrome.
Patients described in this study also show overlapping 
features with other neurodevelopmental disorders caused by 
de novo heterozygous variants in other CHD genes, which 
show intolerance to LOF and missense variants similar to 
that of CHD5. Pathogenic variants in CHD1 lead to a devel-
opmental disorder associated with developmental delay, 
speech apraxia, autism, hypotonia, and facial dysmorphic 
features (Pilarowski et al. 2018). CHD2 pathogenic variants 
cause a developmental and epileptic encephalopathy (Suls 
et al. 2013; Chen et al. 2020). Disease-causing variants in 
CHD7 and CHD8 cause CHARGE syndrome and a syndro-
mic form of autism spectrum disorder, respectively (Vissers 
et al. 2004; Zentner et al. 2010; O’Roak et al. 2011; Merner 
et al. 2016). Finally, pathogenic variants in CHD3 and CHD4 
have recently been described in patients with developmen-
tal delay, intellectual disability, macrocephaly, impaired 
speech, and dysmorphic features (Weiss et al. 2016, 2020; 
Blok et al. 2018; Drivas et al. 2020). Specifically, CHD3 
mutations cause Snijders Blok–Campeau syndrome, which 
is frequently characterized by autism and signs of connective 
tissue laxity (Blok et al. 2018; Drivas et al. 2020). CHD4 
mutations cause Sifrim–Hitz–Weiss syndrome, frequently 
Fig. 3  Facial profiles of patients with CHD5 variants. a–c Patient 1 
age 6 months. d, e Patient 2 age 11 years 4 months. f Patient 4 age 
1 year. g, h Patient 7 age 24 years. i, j Patient 10 age 3 (i) and 5 years 
(j). k–n Patient 13 age 9 months (k), 9 years (l) and 22 years (m, n). 
o, p Patient 14 age 3 years six months (o) and 6 years (p). Facial dys-
morphism was related to craniosynostosis in Patients 1 and 4. Other 
patients displayed subtle facial features, such as high forehead, but no 
consistent facial dysmorphism emerges from the whole panel
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associated with heart malformations as well as numerous 
other findings (Chiari malformation, Moyamoya disease, 
hypogonadism, deafness, and limb malformation) (Weiss 
et al. 2016, 2020). Interestingly, there is an important clini-
cal variability for most CHD-related disorders, which makes 
recognition of these syndromes complicated but yet possible. 
Notably, seizures are rarely observed in patients with CHD4 
variants and occur only in a minority of patient with CHD3 
alterations. Also craniosynostosis has been rarely reported 
in association with variants in other CHD genes (Siakallis 
et al. 2019; Tønne et al. 2020). In our cohort, craniosyn-
ostosis was observed in two individuals belonging to dif-
ferent families and in one patient with a de novo variant. 
The specific association of CHD5 defects with craniosyn-
ostosis remains puzzling based on the reported preferential 
expression of this gene in brain and testis, but possibly sug-
gests that CHD5 might be expressed more broadly at some 
stages of embryonic development or that craniosynostosis 
is linked to an indirect effect of CHD5 alterations on gene 
expression programs that coordinate boundary formation 
or differentiation of overlying cranial neural crest. Interest-
ingly, the knockdown of chd5, which shows an expression 
pattern in adult zebrafish resembling that of CHD5 in adult 
human individuals, results in craniofacial development 
defects including reduced head size and decreased cartilage 
formation in the head, raising the possibility of additional 
conserved roles of CHD5 during vertebrate embryogenesis 
(Bishop et al. 2015). The splicing analysis performed in the 
present study led to the detection of CHD5 transcripts also 
in blood and fibroblasts, suggesting that CHD5 expression 
might not be restricted to brain and testis. Hence, a CHD5 
expression pattern that is broader than previously reported 
could account for the non-brain-related phenotypes observed 
in this cohort of patients.
CHD5 is also a known tumor suppressor gene frequently 
deleted or silenced in diverse human cancers (Bagchi et al. 
2007). None of the patients included in this study have 
had tumors so far, suggesting that germline alterations of 
CHD5, contrary to somatic alterations, do not predispose 
to a higher risk of tumorigenesis, as previously reported for 
other tumor suppressor genes, including for instance genes 
encoding subunits of the SWI–SNF complex or ASXL1 
(Romero and Sanchez-Cespedes 2014; Carlston et  al. 
2017). However, considering the relatively young age of 
this cohort, we cannot rule out an increased risk to develop 
tumors in adult life.
In conclusion, we describe the first cohort of patients with 
heterozygous variants in CHD5, associated with a new syn-
drome mainly characterized by developmental delay, intel-
lectual disability, behavioral symptoms, and epilepsy. Elabo-
rated functional studies are required to understand the impact 
of the variants reported in this study on CHD5 protein levels 
and the NuRD complex during brain development.
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